Abstract
Purposes: This retrospective study evaluated the treatment outcomes and clinical relevance of the KRAS mutation status in Japanese metastatic colorectal cancer patients treated with second-line and later cetuximab-containing therapy. Methods: The subjects comprised 65 patients with metastatic colorectal cancer who received cetuximab-containing therapy. At the start of cetuximab-containing therapy, the KRAS mutation status had been proven to be wild type in 12 patients. Tumors were retrospectively screened for KRAS mutations using direct sequencing. Results: A detailed analysis revealed the presence of 24 wild-type (57.1 %) and 18 mutant tumors (42.9 %). Grade 3-4 neutropenia and anemia were observed in 21 (32.3 %) and nine (13.8 %) patients, respectively. An acne-like rash was observed in 50 patients (76.9 %), and among them three patients (4.6 %) experienced a Grade 3 rash. A KRAS mutation was associated with resistance to cetuximab-containing treatment (11.1 vs. 41.7 % responders among 18 mutant and 36 wild-type patients, respectively; P = 0.03). A KRAS mutation was also associated with poorer survival (MST: 6.9 vs. 14.1 months in 18 mutant and 36 wild-type patients, respectively; P = 0.018). Conclusions: The present results indicated the clinical relevance of KRAS mutations in predicting the efficacy of cetuximab-containing therapy for metastatic colorectal patients in the Japanese population.
| Original language | English |
|---|---|
| Pages (from-to) | 1457-1464 |
| Number of pages | 8 |
| Journal | Surgery today |
| Volume | 44 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
Cite this
Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer : A multicenter study in Japan. / Saeki, Hiroshi; Emi, Yasunori; Kumashiro, Ryuichi; Otsu, Hajime; Kawano, Hiroyuki; Ando, Koji; Ida, Satoshi; Kimura, Yasue; Tokunaga, Eriko; Oki, Eiji; Morita, Masaru; Shimokawa, Mototsugu; Maehara, Yoshihiko.
In: Surgery today, Vol. 44, No. 8, 08.2014, p. 1457-1464.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer
T2 - A multicenter study in Japan
AU - Saeki, Hiroshi
AU - Emi, Yasunori
AU - Kumashiro, Ryuichi
AU - Otsu, Hajime
AU - Kawano, Hiroyuki
AU - Ando, Koji
AU - Ida, Satoshi
AU - Kimura, Yasue
AU - Tokunaga, Eriko
AU - Oki, Eiji
AU - Morita, Masaru
AU - Shimokawa, Mototsugu
AU - Maehara, Yoshihiko
PY - 2014/8
Y1 - 2014/8
N2 - Purposes: This retrospective study evaluated the treatment outcomes and clinical relevance of the KRAS mutation status in Japanese metastatic colorectal cancer patients treated with second-line and later cetuximab-containing therapy. Methods: The subjects comprised 65 patients with metastatic colorectal cancer who received cetuximab-containing therapy. At the start of cetuximab-containing therapy, the KRAS mutation status had been proven to be wild type in 12 patients. Tumors were retrospectively screened for KRAS mutations using direct sequencing. Results: A detailed analysis revealed the presence of 24 wild-type (57.1 %) and 18 mutant tumors (42.9 %). Grade 3-4 neutropenia and anemia were observed in 21 (32.3 %) and nine (13.8 %) patients, respectively. An acne-like rash was observed in 50 patients (76.9 %), and among them three patients (4.6 %) experienced a Grade 3 rash. A KRAS mutation was associated with resistance to cetuximab-containing treatment (11.1 vs. 41.7 % responders among 18 mutant and 36 wild-type patients, respectively; P = 0.03). A KRAS mutation was also associated with poorer survival (MST: 6.9 vs. 14.1 months in 18 mutant and 36 wild-type patients, respectively; P = 0.018). Conclusions: The present results indicated the clinical relevance of KRAS mutations in predicting the efficacy of cetuximab-containing therapy for metastatic colorectal patients in the Japanese population.
AB - Purposes: This retrospective study evaluated the treatment outcomes and clinical relevance of the KRAS mutation status in Japanese metastatic colorectal cancer patients treated with second-line and later cetuximab-containing therapy. Methods: The subjects comprised 65 patients with metastatic colorectal cancer who received cetuximab-containing therapy. At the start of cetuximab-containing therapy, the KRAS mutation status had been proven to be wild type in 12 patients. Tumors were retrospectively screened for KRAS mutations using direct sequencing. Results: A detailed analysis revealed the presence of 24 wild-type (57.1 %) and 18 mutant tumors (42.9 %). Grade 3-4 neutropenia and anemia were observed in 21 (32.3 %) and nine (13.8 %) patients, respectively. An acne-like rash was observed in 50 patients (76.9 %), and among them three patients (4.6 %) experienced a Grade 3 rash. A KRAS mutation was associated with resistance to cetuximab-containing treatment (11.1 vs. 41.7 % responders among 18 mutant and 36 wild-type patients, respectively; P = 0.03). A KRAS mutation was also associated with poorer survival (MST: 6.9 vs. 14.1 months in 18 mutant and 36 wild-type patients, respectively; P = 0.018). Conclusions: The present results indicated the clinical relevance of KRAS mutations in predicting the efficacy of cetuximab-containing therapy for metastatic colorectal patients in the Japanese population.
UR - http://www.scopus.com/inward/record.url?scp=84904390630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904390630&partnerID=8YFLogxK
U2 - 10.1007/s00595-013-0716-0
DO - 10.1007/s00595-013-0716-0
M3 - Article
C2 - 24013837
AN - SCOPUS:84904390630
VL - 44
SP - 1457
EP - 1464
JO - Surgery Today
JF - Surgery Today
SN - 0941-1291
IS - 8
ER -